Please assess the completion status of the following clinical trial:

Trial Title: The Pivotal Study of the Aptus Endovascular AAA Repair System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infrarenal AAA with a maximum diameter ≥ 4.5 cm.~* Infrarenal AAA with at least 12 mm length of non-aneurysmal proximal neck.~* Infrarenal AAA with a proximal neck internal diameter between 19-29 mm.~* Infrarenal AAA with an internal diameter at the aortic bifurcation ≥ 18 mm.~* Infrarenal AAA with an angle of ≤ 60° relative to the long axis of the aneurysm.~* Bilateral iliac artery distal fixation sites ≥ 10 mm in length.~* Bilateral iliac arteries with an internal diameter between 9 and 20 mm.~* Bilateral femoral/iliac arteries with morphology compatible with standard vascular access techniques and vessel size must accommodate a 16F (5.3 mm) or 18F (6.0 mm) delivery system.~Exclusion Criteria:~* Myocardial infarction within past 10 weeks.~* Active systemic infection.~* Ruptured or leaking AAA.~* Mycotic or inflammatory AAA.~* Genetic connective tissue disorders (e.g., Marfans or Ehlers-Danlos Syndromes).~* Concomitant TAA or thoracoabdominal aortic aneurysms.~* Requires emergent AAA surgery.~* Previous AAA repair.~* Patients with a body habitus that would prevent imaging required by the study.~* Patient has significant comorbid conditions that pose undue risk of general anesthesia or endovascular surgery.~* Patient requires additional planned major procedure at the time of AAA repair or within 30 days before or after AAA repair.~* Dialysis dependent renal failure or creatinine \> 2.5 mg/dL.~* Allergy to or intolerance of radiopaque contrast agents.~* Patients with a known sensitivity or allergy to implant materials.~* Patients who cannot discontinue oral anticoagulation or antiplatelet therapy at the time of the study procedure.~* Patients with history of bleeding diathesis or hypercoagulable condition.~* Patients with thrombus, calcification, and/or plaque ≥ 2mm in thickness and/or ≥ 50% (180°) continuous coverage of the vessel circumference in the intended seal zone.~* Patients with irregular shaped calcification and/or plaque that may compromise the fixation and sealing at the proximal or distal implantation sites.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AAA Repair System (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).